Global Hematologic Malignancies Detection Market Research Report 2023

Publication ID:

PB504236453

Publication Date:

June 8, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Hematological malignancy is a major disease that seriously endangers human health. With the invention and application of polymerase chain reaction, immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization, its overall diagnostic level has been significantly improved.
The global Hematologic Malignancies Detection market is projected to reach US$ 5801.1 million in 2029, increasing from US$ 2234.7 million in 2022, with the CAGR of 14.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hematologic Malignancies Detection 91制片厂.
Increasing prevalence of hematological malignancies, emerging new technologies and methods for testing, patient preference for testing treatments, and increasing regulation across the healthcare industry are the key factors driving the growth of hematological malignancies testing market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hematologic Malignancies Detection market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
ArcherDx
Bio-Rad Laboratories
sysmex
Invitae
NeoGenomics Laboratories
Abbott Laboratories
Cancer Genetics
Adaptive Biotechnologies Corporation
Asuragen
Invivoscribe
Nanjing Shihejiyin Technology
Annaroad Gene Technology
BGI Genomics
Segment by Type
Polymerase Chain Reaction
Immunochemistry
Next Generation Sequencing
Fluorescence in Situ Hybridization
Others
Segment by Application
Multiple Myeloma
Myelodysplastic Syndrome
Leukemia
Myeloproliferative Neoplasms
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hematologic Malignancies Detection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematologic Malignancies Detection Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction
1.2.3 Immunochemistry
1.2.4 Next Generation Sequencing
1.2.5 Fluorescence in Situ Hybridization
1.2.6 Others
1.3 Market by Application
1.3.1 Global Hematologic Malignancies Detection Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Multiple Myeloma
1.3.3 Myelodysplastic Syndrome
1.3.4 Leukemia
1.3.5 Myeloproliferative Neoplasms
1.3.6 Lymphoma
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hematologic Malignancies Detection Market Perspective (2018-2029)
2.2 Hematologic Malignancies Detection Growth Trends by Region
2.2.1 Global Hematologic Malignancies Detection Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hematologic Malignancies Detection Historic Market Size by Region (2018-2023)
2.2.3 Hematologic Malignancies Detection Forecasted Market Size by Region (2024-2029)
2.3 Hematologic Malignancies Detection Market Dynamics
2.3.1 Hematologic Malignancies Detection Industry Trends
2.3.2 Hematologic Malignancies Detection Market Drivers
2.3.3 Hematologic Malignancies Detection Market Challenges
2.3.4 Hematologic Malignancies Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Detection Players by Revenue
3.1.1 Global Top Hematologic Malignancies Detection Players by Revenue (2018-2023)
3.1.2 Global Hematologic Malignancies Detection Revenue Market Share by Players (2018-2023)
3.2 Global Hematologic Malignancies Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Detection Revenue
3.4 Global Hematologic Malignancies Detection Market Concentration Ratio
3.4.1 Global Hematologic Malignancies Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Detection Revenue in 2022
3.5 Hematologic Malignancies Detection Key Players Head office and Area Served
3.6 Key Players Hematologic Malignancies Detection Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Detection Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematologic Malignancies Detection Breakdown Data by Type
4.1 Global Hematologic Malignancies Detection Historic Market Size by Type (2018-2023)
4.2 Global Hematologic Malignancies Detection Forecasted Market Size by Type (2024-2029)
5 Hematologic Malignancies Detection Breakdown Data by Application
5.1 Global Hematologic Malignancies Detection Historic Market Size by Application (2018-2023)
5.2 Global Hematologic Malignancies Detection Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hematologic Malignancies Detection Market Size (2018-2029)
6.2 North America Hematologic Malignancies Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hematologic Malignancies Detection Market Size by Country (2018-2023)
6.4 North America Hematologic Malignancies Detection Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hematologic Malignancies Detection Market Size (2018-2029)
7.2 Europe Hematologic Malignancies Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hematologic Malignancies Detection Market Size by Country (2018-2023)
7.4 Europe Hematologic Malignancies Detection Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematologic Malignancies Detection Market Size (2018-2029)
8.2 Asia-Pacific Hematologic Malignancies Detection Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hematologic Malignancies Detection Market Size by Region (2018-2023)
8.4 Asia-Pacific Hematologic Malignancies Detection Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hematologic Malignancies Detection Market Size (2018-2029)
9.2 Latin America Hematologic Malignancies Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hematologic Malignancies Detection Market Size by Country (2018-2023)
9.4 Latin America Hematologic Malignancies Detection Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematologic Malignancies Detection Market Size (2018-2029)
10.2 Middle East & Africa Hematologic Malignancies Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hematologic Malignancies Detection Market Size by Country (2018-2023)
10.4 Middle East & Africa Hematologic Malignancies Detection Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ArcherDx
11.1.1 ArcherDx Company Detail
11.1.2 ArcherDx Business Overview
11.1.3 ArcherDx Hematologic Malignancies Detection Introduction
11.1.4 ArcherDx Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.1.5 ArcherDx Recent Development
11.2 Bio-Rad Laboratories
11.2.1 Bio-Rad Laboratories Company Detail
11.2.2 Bio-Rad Laboratories Business Overview
11.2.3 Bio-Rad Laboratories Hematologic Malignancies Detection Introduction
11.2.4 Bio-Rad Laboratories Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.2.5 Bio-Rad Laboratories Recent Development
11.3 sysmex
11.3.1 sysmex Company Detail
11.3.2 sysmex Business Overview
11.3.3 sysmex Hematologic Malignancies Detection Introduction
11.3.4 sysmex Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.3.5 sysmex Recent Development
11.4 Invitae
11.4.1 Invitae Company Detail
11.4.2 Invitae Business Overview
11.4.3 Invitae Hematologic Malignancies Detection Introduction
11.4.4 Invitae Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.4.5 Invitae Recent Development
11.5 NeoGenomics Laboratories
11.5.1 NeoGenomics Laboratories Company Detail
11.5.2 NeoGenomics Laboratories Business Overview
11.5.3 NeoGenomics Laboratories Hematologic Malignancies Detection Introduction
11.5.4 NeoGenomics Laboratories Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.5.5 NeoGenomics Laboratories Recent Development
11.6 Abbott Laboratories
11.6.1 Abbott Laboratories Company Detail
11.6.2 Abbott Laboratories Business Overview
11.6.3 Abbott Laboratories Hematologic Malignancies Detection Introduction
11.6.4 Abbott Laboratories Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.6.5 Abbott Laboratories Recent Development
11.7 Cancer Genetics
11.7.1 Cancer Genetics Company Detail
11.7.2 Cancer Genetics Business Overview
11.7.3 Cancer Genetics Hematologic Malignancies Detection Introduction
11.7.4 Cancer Genetics Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.7.5 Cancer Genetics Recent Development
11.8 Adaptive Biotechnologies Corporation
11.8.1 Adaptive Biotechnologies Corporation Company Detail
11.8.2 Adaptive Biotechnologies Corporation Business Overview
11.8.3 Adaptive Biotechnologies Corporation Hematologic Malignancies Detection Introduction
11.8.4 Adaptive Biotechnologies Corporation Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.8.5 Adaptive Biotechnologies Corporation Recent Development
11.9 Asuragen
11.9.1 Asuragen Company Detail
11.9.2 Asuragen Business Overview
11.9.3 Asuragen Hematologic Malignancies Detection Introduction
11.9.4 Asuragen Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.9.5 Asuragen Recent Development
11.10 Invivoscribe
11.10.1 Invivoscribe Company Detail
11.10.2 Invivoscribe Business Overview
11.10.3 Invivoscribe Hematologic Malignancies Detection Introduction
11.10.4 Invivoscribe Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.10.5 Invivoscribe Recent Development
11.11 Nanjing Shihejiyin Technology
11.11.1 Nanjing Shihejiyin Technology Company Detail
11.11.2 Nanjing Shihejiyin Technology Business Overview
11.11.3 Nanjing Shihejiyin Technology Hematologic Malignancies Detection Introduction
11.11.4 Nanjing Shihejiyin Technology Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.11.5 Nanjing Shihejiyin Technology Recent Development
11.12 Annaroad Gene Technology
11.12.1 Annaroad Gene Technology Company Detail
11.12.2 Annaroad Gene Technology Business Overview
11.12.3 Annaroad Gene Technology Hematologic Malignancies Detection Introduction
11.12.4 Annaroad Gene Technology Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.12.5 Annaroad Gene Technology Recent Development
11.13 BGI Genomics
11.13.1 BGI Genomics Company Detail
11.13.2 BGI Genomics Business Overview
11.13.3 BGI Genomics Hematologic Malignancies Detection Introduction
11.13.4 BGI Genomics Revenue in Hematologic Malignancies Detection Business (2018-2023)
11.13.5 BGI Genomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

ArcherDx
Bio-Rad Laboratories
sysmex
Invitae
NeoGenomics Laboratories
Abbott Laboratories
Cancer Genetics
Adaptive Biotechnologies Corporation
Asuragen
Invivoscribe
Nanjing Shihejiyin Technology
Annaroad Gene Technology
BGI Genomics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.